Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.coc.0000173186.49719.b1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mean Corpuscular Volume as a Predictive Factor of Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer.
Gastroenterol Res Pract
March 2018
Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Background: The aim of this study was to identify if blood routine parameters and serum tumor marker are potential predictive factors for tumor response to preoperative chemoradiotherapy (CRT) in locally advanced rectal cancer.
Materials And Methods: 55 locally advanced rectal cancer patients were treated with preoperative CRT in this study. The total dose of preoperative radiotherapy was 45 Gy in 25 fractions of 1.
Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer.
Cancer Res Treat
January 2015
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Purpose: Capecitabine is known to increase mean corpuscular volume (MCV). To define the incidence of capecitabine-induced macrocytosis and its association with chemotherapy outcomes, we investigated data of 89 patients with advanced gastric cancer (AGC) who were enrolled in a randomized chemotherapy trial involving capecitabine.
Materials And Methods: Chemotherapy-naïve AGC patients were treated with capecitabine (1,000 mg/m(2)/day on days 1-14) plus cisplatin (75 mg/m(2) on day 1), with or without epirubicin (50 mg/m(2) on day 1).
Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer.
Chemotherapy
January 2015
Department of Oncology, Guastalla Hospital, Guastalla, Italy.
Purpose: Capecitabine has demonstrated significant activity in metastatic breast and colorectal cancer. During the course of treatment with capecitabine, we observed that a relevant number of patients developed elevated levels of the mean corpuscular volume (MCV) of red blood cells.
Methods: This retrospective analysis reviewed treatment with capecitabine in 35 patients with histologically proven advanced breast and colon cancer.
Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer.
Asian Pac J Cancer Prev
January 2015
Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey E-mail :
Background: Capecitabine is an oral fluoropyrimidine derivative which is frequently used alone or in combination regimens for the treatment of metastatic breast cancer. Although overall and progression free survivals have increased in recent years with the use of new generation drugs, predictive factors that would further improve the outcomes are needed. Previous studies have demonstrated the relation between post-treatment increase in mean corpuscular volume (MCV) and predicting therapy response as well as survival.
View Article and Find Full Text PDFCapecitabine-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer.
J BUON
May 2014
Department of Medical Oncology, Katip Celebi University, Izmir Ataturk Training and Research Hospital, Izmir, Turkey.
Purpose: Erythrocyte mean corpuscular volume (MCV) increase has been described in patients treated with capecitabine. In this study, we sought to evaluate the potential association of the erythrocyte MCV increase with tumor response and survival in patients with metastatic colorectal cancer (mCRC) treated with capecitabine.
Methods: A retrospective review of 131 patients with mCRC who were treated with capecitabine for at least 3 months at the Izmir Training and Research Hospital was undertaken.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!